Daré Bioscience, Inc. (DARE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Daré Bioscience, Inc. (DARE) is up 10.9% since the beginning of the year. At $2 per share, DARE is trading 76.7% below its 52-week high of $9. Investors who bought $1,000 worth of DARE shares 5 years ago would now be looking at an investment worth $140.

Daré Bioscience, Inc. (DARE) has returned 10.88% so far this year and -29.37% over the past 12 months. Over the last ten years, DARE has returned -38.83% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Apr 10, 2014, DARE's average daily return is +0.02%, while the average monthly return is -1.72%.

Historically, 35% of months were positive and 65% were negative. The best month was Feb 2024 with a return of +76.6%, while the worst month was Aug 2016 at -64.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 11 months.

On a daily basis, DARE closed higher 43% of trading days. The best single day was Jul 5, 2017 with a return of +143.7%, while the worst single day was Mar 20, 2017 at -62.4%.

Daré Bioscience, Inc. has an annualized alpha of -6.08%, beta of 0.82, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since April 11, 2014.

• This stock participated in 203.58% of S&P 500 Index downside but only -18.69% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

DARE ranks 28 for risk / return — below 28% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Daré Bioscience, Inc. (DARE) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Daré Bioscience, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Daré Bioscience, Inc. was 99.90%, occurring on Mar 19, 2026. The portfolio has not yet recovered.

The current Daré Bioscience, Inc. drawdown is 99.83%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Daré Bioscience, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Daré Bioscience, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.